Clinical outcomes and prognostic factors for gastric cancer patients with bone metastasis

Mikami, Jota; Kimura, Yutaka; Makari, Yoichi; Fujita, Junya; Kishimoto, Tomoya; Sawada, Genta; Nakahira, Shin; Nakata, Ken; Tomita, Masaki; Ohzato, Hiroki

doi:10.1186/s12957-016-1091-2

Cited by 37 publications

(30 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The metastatic rate to above four sites were much higher than previous literature reports, which were 13.5% for liver metastasis,15 0.5%‐0.96% for lung metastasis,16, 17, 18 0.9%‐3.8% for bone metastasis19, 20, 21, 22 and 0.16%‐0.69% for brain metastasis 23, 24. The actual frequency of metastasis to bone and brain originating from GC was underestimated because usually bone and brain imaging was not performed as a routine evaluation and asymptomatic metastasis might be overlooked 25, 26. In our study, we found that the frequency of bone metastasis was similar to lung metastasis.…”

Section: Discussionmentioning

confidence: 99%

Frequency and clinicopathological features of metastasis to liver, lung, bone, and brain from gastric cancer: A SEER‐based study

et al. 2018

View full text Add to dashboard Cite

The hematogenous metastatic pattern of gastric cancer (GC) was not fully explored. Here we analyzed the frequency and clinicopathological features of metastasis to liver, lung, bone, and brain from GC patients. Data queried for this analysis included GC patients from the Surveillance, Epidemiology, and End Results Program database from 2010 to 2014. All of statistical analyses were performed using the Intercooled Stata 13.0 (Stata Corporation, College Station, TX). All statistical tests were two‐sided. Totally, there were 19 022 eligible patients for analysis. At the time of diagnosis, there were 7792 patients at stage IV, including 3218 (41.30%) patients with liver metastasis, 1126 (14.45%) with lung metastasis, 966 (12.40%) with bone metastasis and 151 (1.94%) with brain metastasis. GC patients with lung or liver metastasis have a higher risk of bone and brain metastasis than those without lung nor liver metastasis. Intestinal subtype had significantly higher rate of liver and lung metastasis, while diffuse type was more likely to have bone metastasis. Proximal stomach had significantly higher risk to develop metastasis than distal stomach. African‐Americans had the highest risk of liver metastasis and Caucasian had the highest prone to develop lung and brain metastasis. The median survival for patients with liver, lung, bone, and brain metastasis was 4 months, 3 months, 4 months and 3 months, respectively. It is important to evaluate the status of bone and brain metastasis in GC patients with lung or liver metastasis. Knowledge of metastatic patterns is helpful for clinicians to design personalized pretreatment imaging evaluation for GC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Frequency and clinicopathological features of metastasis to liver, lung, bone, and brain from gastric cancer: A SEER‐based study

et al. 2018

View full text Add to dashboard Cite

show abstract

“…[8][9][10] Imaging examinations like bone scan, MRI, or PET-CT were more appropriate compared to laboratory indexes like ALP, LDH, and tumor markers in some researches. [ 19,22] Thus, method and frequency of bone scan need to be estimated in further study.…”

Section: Discussionmentioning

confidence: 99%

“…Since there had not clear guideline for treatment of GCBM, some researches thought that chemotherapy and bisphosphonate therapy will improve overall survival and prolong time to the first SRE. [ 7,8,10,[17][18][19] Besides, radiotherapy may be quite effective to relieve severe pain and to prevent fractures in GCBM but with no improvement in survival. [ 8,10,20] However, the role of surgery in GCBM had not been identified yet.…”

Section: A Korean Research [mentioning

confidence: 99%

See 1 more Smart Citation

Proportion and Prognosis of Bone Metastases from Gastric Cancer in SEER database

Sun¹,

Chen²,

Zhen³

et al. 2019

Preprint

View full text Add to dashboard Cite

Purpose The purpose of this study was to analyze the proportion and prognosis of bone metastases at diagnosis of gastric cancer using population-based data from SEER. Patients and methods Patients with gastric cancer and bone metastases (GCBM) at the time of diagnosis in advanced gastric cancer were identified using the Surveillance, Epidemiology and End Result (SEER) database of the National Cancer Institute. Multivariable logistic and Cox regression were performed to identify predictors of the presence of GCBM at diagnosis and factors associated with all-cause mortality and gastric cancer-specific mortality. Survival curves were obtained according to the Kaplan-Meier method and compared using the log-rank test. Results We identified 975 patients with gastric cancer and bone metastases at the time of diagnosis, representing 5.31% of the entire cohort and 13.35% of the subset with metastatic disease to any distant site. Among entire cohort, multivariable logistic regression identified five factors (lower age, diffused-type, adverse pathology grade, N1 staging and presence of more extraosseous metastases to liver, lung and brain.) as positive predictors of the presence of bone metastases at diagnosis. Median survival among the entire cohort with GCBM was 4.0 months (interquartile range: 1.0-8.0mo). Multivariable Cox model in SEER cohort confirmed two factors (non-cardia stomach and absence of chemotherapy) as negative predictors for overall survival. We also found poor survival in non-surgical patients using Fine and Gray’s competing risk regression model. Conclusion The findings of this study provided population-based estimates of the proportion and prognosis for GCBM at time of diagnosis. These findings provided guidance for screening and treatment of GCBM patients. Chemotherapy may make benefit for overall survival, but the role of surgery remained to be determined by further research.

show abstract

“…Furthermore, the patients with invasion and metastasis have poorer prognosis. 4,5 Therefore, it is crucial to explore the molecular mechanism underlying the progression of GC.…”

Section: Introductionmentioning

confidence: 99%

<p>MicroRNA Profile Identifies miR-6165 Could Suppress Gastric Cancer Migration and Invasion by Targeting STRN4</p>

Zhu¹,

Li²,

Cao³

et al. 2020

OTT

View full text Add to dashboard Cite

Background: Recent studies showed that aberrant expression of miRNAs causes tumorsuppressing or promoting effects in various cancers including gastric cancer (GC). Our previous studies showed that lots of miRNAs and mRNA expressed differentially in GC and normal tissues. However, the critical miRNAs and mRNA need to be clarified. Materials and Methods: Microarray sequencing was used to profile the differential expression of miRNAs and mRNA in GC and normal tissues. Bioinformatics analysis and database prediction were used to search the critical miRNAs and mRNA. Real-time quantitative polymerase chain reaction (RT-qPCR), luciferase reporter assay, immunohistochemistry (IHC), wound healing assay and transwell assay were used to clarify the relationship between the target miRNAs and mRNA. Statistical analysis was used to seek their value of diagnosis and prognosis. Results: We identified microRNA-6165 (miR-6165) as a novel cancer-related miRNA in GC through high-throughput microarray sequencing. By bioinformatics analysis and luciferase reporter assay, we found STRN4 was the target of miR-6165. Via a series of cell experiments, we determined that miR-6165 suppressed GC cells migration and invasion by targeting STRN4. Also, we discovered the potential diagnosis and prognosis value of miR-6165 and STRN4. Conclusion: It was found that miR-6165 might suppress GC migration and invasion by targeting STRN4 in vitro, and the further research should focus more on the potential diagnosis and prognosis value of miR-6165 and STRN4 in gastric cancer patients.

show abstract

Clinical outcomes and prognostic factors for gastric cancer patients with bone metastasis

Cited by 37 publications

References 16 publications

Frequency and clinicopathological features of metastasis to liver, lung, bone, and brain from gastric cancer: A SEER‐based study

Frequency and clinicopathological features of metastasis to liver, lung, bone, and brain from gastric cancer: A SEER‐based study

Proportion and Prognosis of Bone Metastases from Gastric Cancer in SEER database

<p>MicroRNA Profile Identifies miR-6165 Could Suppress Gastric Cancer Migration and Invasion by Targeting STRN4</p>

Contact Info

Product

Resources

About